RecruitingPhase 1NCT04055818

A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

Studying Sickle cell disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
EpiDestiny, Inc.
Principal Investigator
Robert Molokie
University of Illinois at Chicago College of Medicine
Intervention
Nicotinamide(drug)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
2020 – 2027

Study locations (1)

Collaborators

National Institutes of Health (NIH) · National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04055818 on ClinicalTrials.gov

Other trials for Sickle cell disease

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell disease →

← Back to all trials